Nuvalent CEO to Present at J.P. Morgan Healthcare Conference on January 13, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Conference Appearance: Nuvalent's CEO, Dr. James Porter, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:00 a.m. PT in San Francisco, showcasing the company's latest advancements in targeted cancer therapies, which is expected to attract investor interest.
- Live Webcast: The presentation will be available via live webcast on the company's website in the Investors section and archived for 30 days post-event, ensuring that investors unable to attend in real-time can access critical information, thereby enhancing company transparency and investor trust.
- Company Background: Nuvalent focuses on developing precisely targeted therapies for cancer, leveraging deep expertise in chemistry and structure-based drug design to overcome the limitations of existing therapies, which positions the company for significant market potential.
- R&D Pipeline: The company is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, demonstrating its strong research capabilities and competitive edge in the cancer treatment market.
NUVL
$103.8+Infinity%1D
Analyst Views on NUVL
Wall Street analysts forecast NUVL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUVL is 139.60 USD with a low forecast of 105.00 USD and a high forecast of 158.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 101.410
Low
105.00
Averages
139.60
High
158.00
Current: 101.410
Low
105.00
Averages
139.60
High
158.00
About NUVL
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. It is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
